Navidea Biopharmaceuticals comes up short on the top-line

Navidea Biopharmaceuticals (NAVB) puts up a pretty substantial top-line miss for Q3.

Lymphoseek sales for the period: $144K.

NAVB emphasizes a 600% Q/Q increase in unit dose sales and a "repeat-order rate of approximately 90%."

Cash as of September 30: $44.6M.

CEO Mark Pykett says the company is "seeing good momentum in many ... key parameters [including] multi-fold increases in unit sales Q/Q, a high frequency of repeat and multi-dose ordering, an increase in total accounts ordering, strong new user accrual, and encouraging formulary placement activity." (PR)

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs